HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
about
A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expressionCurrent and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.Epigenetics as a therapeutic target in breast cancer.Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.MicroRNA-mediated epigenetic targeting of Survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer.Multidrug-resistant breast cancer: current perspectives.TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms.Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.Combination strategies to enhance antitumor ADCC.HDAC inhibitor-based therapies: can we interpret the code?Emerging targeted agents in metastatic breast cancer.Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies.Entinostat for the treatment of breast cancer.Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodiesThe KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma.Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.Combination of bendamustine and entinostat synergistically inhibits proliferation of multiple myeloma cells via induction of apoptosis and DNA damage response.A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research GTargeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells
P2860
Q33991817-050A077D-4939-4A70-ABDB-3501CD52F9FCQ35000789-57E47D02-EA3E-40AD-9138-EC5079EB7D31Q36449057-DE792015-BFFA-4619-8754-D7D4C80AD91FQ37190106-032E4F5B-7A64-4E67-99C1-0BE4E6B2FA72Q37437269-7640ABD5-2E2A-4A5F-A04D-1D075CA6AEA3Q37593383-772F5B5C-69A2-432F-BB87-AF86B8C7FC8DQ37672563-208049D9-A2BD-4653-B5EF-E7AFD1169312Q37690272-F080239B-CAA7-496C-A3F4-37AE59E5E36DQ38014085-7C050749-58D0-4066-9C83-4B1978662D0BQ38058971-6DE8FAA9-9D86-4D3C-A72F-67CBB8BD714DQ38086421-01796D64-D9B1-4D3C-AA75-6C431AD607E5Q38364887-DEB07F25-91DA-47A7-95B5-B05095563191Q38674317-4006D46D-29F1-4422-8F42-505C70D1E118Q38927187-A0B6C74A-E58B-4B4D-8648-DB9B531EB2F3Q39061338-A36692B4-DE34-4A57-A943-0B250903D8EAQ39177415-133DAC5B-4B1A-4640-94B3-BD3D0CB42206Q39185574-0F47A6DF-050B-4EEF-8856-C934F0AAC0A5Q48758277-AA352F41-487B-428C-A7AF-F584E1D6F664Q58796351-09F36A5A-CD4F-4843-AACE-5895A9F5235E
P2860
HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
HDAC inhibitor SNDX-275 enhanc ...... ercome trastuzumab resistance.
@en
HDAC inhibitor SNDX-275 enhanc ...... ercome trastuzumab resistance.
@nl
type
label
HDAC inhibitor SNDX-275 enhanc ...... ercome trastuzumab resistance.
@en
HDAC inhibitor SNDX-275 enhanc ...... ercome trastuzumab resistance.
@nl
prefLabel
HDAC inhibitor SNDX-275 enhanc ...... ercome trastuzumab resistance.
@en
HDAC inhibitor SNDX-275 enhanc ...... ercome trastuzumab resistance.
@nl
P2093
P1433
P1476
HDAC inhibitor SNDX-275 enhanc ...... vercome trastuzumab resistance
@en
P2093
Choon-Kee Lee
Shuiliang Wang
XiaoHe Yang
Xiaoping Huang
P356
10.1016/J.CANLET.2011.03.019
P407
P50
P577
2011-04-16T00:00:00Z